Clinical Trial Update: PegIntron Versus IntronA in CMAJCC Stage II (EADO 2001/CMII Trial) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing pegylated interferon alfa-2b (PegIntron) with interferon alfa-2b (IntronA) in CMAJCC Stage II; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Melanoma

Drugs mentioned

• IntronA (interferon alfa-2b)
• PegIntron (pegylated interferon alfa-2b)

Snippet

Sponsor: University Hospital, Bordeaux | Conditions: Melanoma, Neoplasm Metastasis | Phase 3 | Status: COMPLETED